blebbistatinKD025Y-27632rh-TGFβSkin fibrosissystemic sclerosis (SSc)SSc
…blasts stimulated with rh- TGFβ (n=10) using the NMII inhibitor blebbistatin, the pan-ROCK inhibitor Y-27632, and the ROCK2-selective inhibi…
10,506articles mentioning drugs
58,393drug mentions
9,496distinct drugs extracted
0%of mentions human-reviewed
All extracted drugs
Showing 7,621–7,680 of 9,496, ordered by supporting articles. Choose a drug to see its evidence.
angiotensin II1angiotensin II inhibitors1angiotensin II receptor blocker1angiotensin converting enzyme (ACE) inhibitor1angiotensin converting enzyme inhibitors-angiotensin II receptor blockers1anifrolumabAbstract1anlotinib-induced1antacid1anthelmintic medication1anthelmintics1anti PD-11anti-4-1BB1anti-B7-H3 antibody‒drug conjugate1anti-BAFF1anti-CD38 mAb1anti-CD38 monoclonal antibodies1anti-CD401anti-CD40 agonist antibody1anti-CD47 monoclonal antibody1anti-CGRP monoclonal antibodies1anti-CTLA-4 antibody1anti-CTLA-4 mAb1anti-CTLA4 antibody1anti-HER2 antibody-drug conjugates1anti-Ly6G1anti-MDA5 antibody1anti-Mullerian Hormone1anti-Müllerian hormone1anti-OA pharmacological agents1anti-OX401anti-PD-(L)1-based1anti-PD-1 ICB1anti-PD-L1 avelumab1anti-Parkinson’s drugs1anti-Sjögren’s syndrome antigen A1anti-TIM-31anti-Th/To-positive1anti-VEGF agents1anti-VEGFR21anti-anginal medication1anti-cancer compounds1anti-cytotoxic T lymphocyte-associated antigen-4 immune checkpoint inhibitors1anti-diabetic agents1anti-fibrotic medications1anti-histamines1anti-hypertensive drugs1anti-infectious agents1anti-inflammatory drugs1anti-inflammatory reliever1anti-interferon1anti-oestrogen medications1anti-pan γδ x CD1231anti-pan γδ x CD123 bispecific antibody1anti-programmed cell death protein 11anti-programmed cell death protein 1 (PD1)1anti-programmed cell death protein-1/programmed death-ligand 11anti-programmed death (ligand) 11anti-programmed death-ligand 1 (PD-(L)1)1anti-programmed death-ligand 1 (PD-L1)1anti-programmed death-ligand 1 antibodies1
Articles mentioning drugs
10,506 articles · page 111 of 876Glabrescione BShhSonic Hedgehog
…nalysis of HUVEC and HMDECs treated with Shh, TGFβ or TGFβ plus Glabrescione B for 5 days showed 408 DEGs shared by TGFβ and Shh. Reactome enr…
tocilizumabmycophenolate mofetilrituximababataceptABATCZRTXcyclophosphamideazathioprinemethotrexate+4 more
…analyze long term outcome of patients with SSc-ILD treated with tocilizumab (TCZ), rituximab (RTX), and abatacept (ABA) which became availa…
P.211 Ruxolitinib therapy in pansclerotic morphea refractory to autologous stem-cell transplantation
ruxolitinibMycophenolate mofetilcyclophosphamiderituximababatacepttocilizumabmethotrexatePansclerotic morphea (PSM)
… kinase (JAK) – STAT signalling in PSM pathogenesis, suggesting ruxolitinib, a JAK 1/2 inhibitor, as potential therapeutic option [N Engl J…
efgartigimodrecombinant human hyaluronidase PH20rHuPH20PH20 SCHealth Assessment QuestionnaireSystemic SclerosisSystemic sclerosis (SSc)NCT06655155interstitial lung disease
…SSc will be randomized 2:1 to receive weekly administrations of efgartigimod or placebo PH20 SC (coformulated with recombinant human hyaluro…
rituximabmethotrexatemycophenolatemyocphenolatecyclophosphamideHealth Assessment QuestionnaireVisual Analogue Scalesystemic sclerosis (SSc)European Scleroderma Study GroupSt George's Respiratory Questionnaire+1 more
…SF-36).Conclusions These findings suggest that long-term use of rituximab provides sustained clinical benefit in patients with progressiv…
tofacitinibcyclophosphamiderituximabmethotrexatelcSSc
…slowing lung function decline in lcSSc. In addition, a trial of tofacitinib with 40 (61%) lcSSc patients showed that this drug was more eff…
PM-Scl75PM-Scl100Ro52Scleromyositisdermatomyositissystemic sclerosisIIMsystemic sclerosis-relatedSSc-polymyositisuniversity hospital+1 more
… are limited. Our study aimed to evaluate changes in PM-Scl100, PM-Scl75, and anti-Ku antibody positivity before and during the pandemic…
TirofibanNCT04751708Acute basilar artery occlusion (BAO)EVT
…; P=0.012 for stroke etiology×tirofiban interaction).Conclusion Tirofiban may be associated with favorable outcomes in non-AS BAO without…
baricitinibmethotrexateMTXUAundifferentiated arthritisRheumatoid Arthritissymptomatic therapy
…ty over 3 months compared with NSAIDs, with the improvement for baricitinib reaching statistical significance. Over 12 months, disease acti…
PegenzileukincemiplimabpembrolizumabMMcutaneous squamous cell carcinomaCSCC
…ombinations in patients with MM (Cohort A) and CSCC (Cohort B). Pegenzileukin was given at two dose levels (16 µg/kg: Cohort A1 and B1 and 24…